k-haler is a new asthma inhaler that has been designed to make patient use simple and easy. It is a breath activated device that requires lower inhalation force to trigger than most other similar inhalers. This also eliminates the need for asthma patients to coordinate their breathing and button pushing. Although designed for asthmatics, the technology within the k-haler is potentially suitable for a range of inhaled products. Its modern, user friendly, compact and simple design, combined with clever engineering, means k-haler is a truly world class device.

The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems.